Medicine:Clinical endocannabinoid deficiency syndrome
From HandWiki
Clinical endocannabinoid deficiency (CECD) is a medical theory that proposes that a deficiency of endocannabinoids is the underlying pathophysiology of migraines, fibromyalgia, and irritable bowel syndrome.[1][2] The deficiency may sometimes start in the womb as a result of maternal obesity.[3] The nature of the syndrome and existence of CECD as a clinically meaningful condition have been called into question.[4]
References
- ↑ Russo, EB (2004). "Clinical endocannabinoid deficiency (CECD): Can this concept explain therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions?". Neuro Endocrinology Letters 25 (1–2): 31–9. PMID 15159679.
- ↑ Russo, EB (2016). "Clinical Endocannabinoid Deficiency Reconsidered: Current Research Supports the Theory in Migraine, Fibromyalgia, Irritable Bowel, and Other Treatment-Resistant Syndromes.". Cannabis and Cannabinoid Research 1 (1): 154–165. doi:10.1089/can.2016.0009. PMID 28861491.
- ↑ "Fetal Syndrome of Endocannabinoid Deficiency (FSECD) in Maternal Obesity". Medical Hypotheses 96: 35–38. 2016. doi:10.1016/j.mehy.2016.09.021. PMID 27959272.
- ↑ Cogan, PS (2020). "Practical Considerations of Hypotheses and Evidence in Cannabis Pharmacotherapy: Refining Expectations of Clinical Endocannabinoid Deficiency". Journal of Dietary Supplements 17 (5): 608–624. doi:10.1080/19390211.2020.1769246. PMID 32449630.
 |  |
